The drug is licensed for the treatment of active and progressive arthritis in adults unresponsive to other therapy.
NICE has made the recommendation because research indicates that golimumab is not more cost-effective than other available options.
A spokesman said: 'NICE currently recommends adalimumab, etanercept and infliximab for the treatment of psoriatic arthritis in people who have peripheral arthritis. The cost-effectiveness analyses found that golimumab was not the most cost effective of the available options currently recommended by NICE.'
A secondary reason for the guidance was uncertainty about possible harmful side-effects of taking the drug, as a long-term follow up on adverse outcomes is ongoing.
The spokesman added: 'Based on the available evidence, golimumab was expected to be more costly than estimated in the economic model and less cost effective than etanercept, and so could not be considered a good use of NHS resources.'
The draft guidance is currently open to consultation.